큐리언트
Financials
Valuation Metrics
큐리언트's Market Cap is ₩8370B. At end of 2025 it was ₩1.1T. Ranked #344 of 2,419 in KR market (top 14%), #105 of 1,638 on KOSDAQ (top 6%), #38 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-08)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 837.01B KRW | KR#344/2,419 Sec#38/231 |
| Revenue | 7.07B KRW | KR#2,316/2,419 Sec#185/231 |
| Net Income | -39.77B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 61.99B KRW | KR#2,085/2,419 Sec#180/231 |
| Net Assets | 39.19B KRW | KR#2,062/2,419 Sec#182/231 |
| Employees | 33 | KR#2,181/2,419 Sec#202/231 |
| Value | ||
| P/B | 21.36x | KR#2,402/2,419 Sec#225/231 |
| P/S | 118.43x | KR#2,391/2,419 Sec#210/231 |
| FCF Yield | -3.43% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -101.48% | KR#2,346/2,419 Sec#219/231 |
| ROA | -64.16% | KR#2,378/2,419 Sec#220/231 |
| Op. Margin | -520.53% | KR#2,363/2,419 Sec#205/231 |
| Revenue Growth | -20.12% | KR#2,128/2,419 Sec#193/231 |
| Financial Health | ||
| Debt Ratio | 58.18% | KR#1,073/2,419 Sec#125/231 |
| Total Debt | 9.42B KRW | KR#1,644/2,419 Sec#149/231 |
| FCF | -28.73B KRW | KR#1,980/2,419 Sec#191/231 |
| Cash | 21.04B KRW | KR#1,223/2,419 Sec#88/231 |
| Current Ratio | 10.35x | KR#92/2,419 Sec#21/231 |
| Performance | ||
| 1Y Return | 21.79% | KR#583/2,419 Sec#38/231 |
| 1M Return | -2.83% | KR#1,526/2,419 Sec#152/231 |
| From 52W High | -64.55% | KR#2,047/2,419 Sec#176/231 |
| 1Y MDD | -70.83% | KR#2,023/2,419 Sec#177/231 |
| Trading | ||
| Volume | 197,349 shares | KR#509/2,419 Sec#55/231 |
| Trading Value | 4.34B KRW | KR#397/2,419 Sec#46/231 |
| Foreign Own. | 3.15% | KR#1,240/2,419 Sec#114/231 |
| Per Share | ||
| EPS | -1,060 KRW | KR—/2,419 Sec—/231 |
| BPS | 1,044 KRW | KR#2,301/2,419 Sec#209/231 |
Company Info
QURIENT was established in 2008 to commercialize research from the Korea Pasteur Institute and listed on KOSDAQ in 2016. Specializing in pharmaceutical research and development, it possesses innovative new drug pipelines including MOCASICLIP, QP101, and AADRIXETINIB. The company prioritizes anti-cancer and autoimmune disease projects through a strategic alliance with the Max Planck Institute and pursues revenue generation by developing combination therapies with MSD's KEYTRUDA. QURIENT is headquartered in Seongnam-si, Gyeonggi-do.